Shinobu Tamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shinobu Tamura has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Yusuke Yamashita
Department of Hematology/Oncology, Wakayama Medical University, Wakayama 6418509, Japan
18 shared publications - Takashi Sonoki
Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
13 shared publications Takashi Sonoki
Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
10 shared publicationsTokuzo Fujimoto
Department of Internal Medicine, Kinan Hospital, Japan
9 shared publicationsAkinori Nishikawa
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
8 shared publicationsToshiki Mushino
Department of Hematology/Oncology, Wakayama Medical University, Japan
8 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9) , e70750
First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review
Striatin–anaplastic lymphoma kinase (STRN–ALK) is a rare fusion variant in non‐small cell lung cancer (NSCLC), and the efficacy of first‐line lorlatinib for this subgroup is poorly defined. We report a 45‐year‐old treatment‐naïve male with STRN‐ALK‐positive lung adenocarcinoma and symptomatic brain metastases. Following stereotactic radiosurgery for intracranial lesions, the patient initiated lorlatinib at 100 mg once daily as the first systemic therapy. After starting treatment, neuropsychiatric side effects necessitated a gradual reduction in dosage to 75 mg and then to 50 mg. The patient achieved a durable partial response with sustained intracranial disease control for over 1 year. Adjusting the dosage improved tolerability without compromising efficacy, allowing for ongoing treatment. This case demonstrates that first‐line lorlatinib can achieve durable systemic and intracranial disease control in STRN–ALK–positive NSCLC, including in patients presenting with brain metastases, while maintaining antitumor efficacy despite dose reduction.
- 3 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9) , e70750
Open AccessFirst‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review
Striatin–anaplastic lymphoma kinase (STRN–ALK) is a rare fusion variant in non‐small cell lung cancer (NSCLC), and the efficacy of first‐line lorlatinib for this subgroup is poorly defined. We report a 45‐year‐old treatment‐naïve male with STRN‐ALK‐positive lung adenocarcinoma and symptomatic brain metastases. Following stereotactic radiosurgery for intracranial lesions, the patient initiated lorlatinib at 100 mg once daily as the first systemic therapy. After starting treatment, neuropsychiatric side effects necessitated a gradual reduction in dosage to 75 mg and then to 50 mg. The patient achieved a durable partial response with sustained intracranial disease control for over 1 year. Adjusting the dosage improved tolerability without compromising efficacy, allowing for ongoing treatment. This case demonstrates that first‐line lorlatinib can achieve durable systemic and intracranial disease control in STRN–ALK–positive NSCLC, including in patients presenting with brain metastases, while maintaining antitumor efficacy despite dose reduction.
- Open Access
- 20 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110904
Population-level impact of universal early AED implementation on out-of-hospital cardiac arrest outcomes: a machine learning analysis using synthetic patient data of 45-year projection study from Japan
- 20 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110904
Open AccessPopulation-level impact of universal early AED implementation on out-of-hospital cardiac arrest outcomes: a machine learning analysis using synthetic patient data of 45-year projection study from Japan
- Open Access
- 24 September 2025
- Published by Springer Nature in BMC Emergency Medicine
- Vol. 25 (1) , 1-9
Association between endotracheal intubation and outcomes of nonshockable out-of-hospital cardiac arrest in Japan
Patients with nonshockable out-of-hospital cardiac arrest (OHCA) have poor outcomes compared with those with shockable rhythm. The optimal strategy for advanced airway management (AAM) for these patients remains controversial. This study aimed to compare outcomes between prehospital endotracheal intubation (ETI) and supraglottic airway (SGA) for adults with witnessed and nonshockable OHCA. We compared the outcomes according to airway management using a nationwide, population-based Japanese registry (All-Japan Utstein Registry) between 2005 and 2021. The study population included adults with witnessed, nontraumatic, nonshockable OHCA who received prehospital AAM by emergency medical service (EMS) personnel. The outcomes were return of spontaneous circulation (ROSC), 1-month overall survival, and 1-month survival with a favorable neurological outcome, defined as a Cerebral Performance Category score of 1 or 2. To adjust for confounding factors between the ETI and SGA groups, we used propensity score analysis with inverse probability of treatment weighting (IPTW) and performed a sensitivity analysis using overlap weighting. A total of 147,088 patients were included: 30,797 (20.9%) received ETI and 116,291 (79.1%) received SGA. After IPTW adjustment, patients receiving ETI had significantly higher rates of ROSC (19.3% vs. 11.1%; odds ratio [OR] 1.51; 95% confidence interval [CI] 1.48–1.54), 1-month survival (6.4% vs. 4.5%, OR 1.44; 95%CI 1.40–1.49), and 1-month survival with favorable neurological outcomes (1.0% vs. 1.0%, OR 1.11; 95%CI 1.04–1.20) than those receiving SGA. The sensitivity analysis confirmed robust associations for ROSC (OR 1.53; 95%CI 1.45–1.61) and 1-month survival (OR 1.48; 95%CI 1.36–1.60), but the association with favorable neurological outcome was not statistically significant (OR 1.11; 95%CI 0.93–1.34). In this Japanese nationwide Utstein registry cohort study with IPTW adjustment, for adult witnessed OHCA patients with initial nonshockable rhythm, prehospital ETI was associated with significantly higher rates of ROSC and 1-month survival, compared to prehospital SGA. These findings suggest that ETI, when performed by EMS personnel, has the potential to improve outcomes in these patients with OHCA.
- 24 September 2025
- Published by Springer Nature in BMC Emergency Medicine
- Vol. 25 (1) , 1-9
Open AccessAssociation between endotracheal intubation and outcomes of nonshockable out-of-hospital cardiac arrest in Japan
Patients with nonshockable out-of-hospital cardiac arrest (OHCA) have poor outcomes compared with those with shockable rhythm. The optimal strategy for advanced airway management (AAM) for these patients remains controversial. This study aimed to compare outcomes between prehospital endotracheal intubation (ETI) and supraglottic airway (SGA) for adults with witnessed and nonshockable OHCA. We compared the outcomes according to airway management using a nationwide, population-based Japanese registry (All-Japan Utstein Registry) between 2005 and 2021. The study population included adults with witnessed, nontraumatic, nonshockable OHCA who received prehospital AAM by emergency medical service (EMS) personnel. The outcomes were return of spontaneous circulation (ROSC), 1-month overall survival, and 1-month survival with a favorable neurological outcome, defined as a Cerebral Performance Category score of 1 or 2. To adjust for confounding factors between the ETI and SGA groups, we used propensity score analysis with inverse probability of treatment weighting (IPTW) and performed a sensitivity analysis using overlap weighting. A total of 147,088 patients were included: 30,797 (20.9%) received ETI and 116,291 (79.1%) received SGA. After IPTW adjustment, patients receiving ETI had significantly higher rates of ROSC (19.3% vs. 11.1%; odds ratio [OR] 1.51; 95% confidence interval [CI] 1.48–1.54), 1-month survival (6.4% vs. 4.5%, OR 1.44; 95%CI 1.40–1.49), and 1-month survival with favorable neurological outcomes (1.0% vs. 1.0%, OR 1.11; 95%CI 1.04–1.20) than those receiving SGA. The sensitivity analysis confirmed robust associations for ROSC (OR 1.53; 95%CI 1.45–1.61) and 1-month survival (OR 1.48; 95%CI 1.36–1.60), but the association with favorable neurological outcome was not statistically significant (OR 1.11; 95%CI 0.93–1.34). In this Japanese nationwide Utstein registry cohort study with IPTW adjustment, for adult witnessed OHCA patients with initial nonshockable rhythm, prehospital ETI was associated with significantly higher rates of ROSC and 1-month survival, compared to prehospital SGA. These findings suggest that ETI, when performed by EMS personnel, has the potential to improve outcomes in these patients with OHCA.
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1440-1449
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma
No standard of care for older patients with aggressive adult T-cell leukemia/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) every 2 weeks with mogamulizumab (Moga; Moga-CHOP-14) for older patients with untreated ATL. In this multicenter phase 2 trial, patients aged ≥66 years and those aged 56 to 65 years ineligible for transplantation received 6 cycles of Moga-CHOP-14, followed by 2 cycles of Moga monotherapy. The primary end point was 1-year progression-free survival (PFS). Secondary end points were the complete response (CR) rate, overall response rate (ORR), overall survival (OS), 1-year event-free survival (EFS), and safety. We also investigated the impact of CC chemokine receptor 4 (CCR4) mutation and Moga-associated cutaneous adverse events (cAEs) on PFS and OS. The study protocol was amended to allow the dosing interval to be extended to 21 days at the physician’s discretion. Among 48 evaluable patients, the 1-year PFS was 36.2% (90% confidence interval, 24.9-47.6), with a median follow-up of 1.6 years. The 1-year OS and EFS were 66.0% and 29.9%, respectively. CR and ORR were 64.6% and 91.7%. No unexpected toxicities were observed. Of 47 patients who received ≥2 cycles of CHOP, 20 (42.6%) received CHOP-14, among whom 12 (25.5%) completed 6 cycles. CCR4 mutation and Moga-associated cAEs were associated with better OS. This study showed that Moga-CHOP significantly improved PFS, although the optimal interval for CHOP remains undetermined. Moga-CHOP is now considered a preferable first-line treatment for this patient population. This trial was registered at https://jrct.mhlw.go.jp/en-top as #jRCTs041180130.
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1440-1449
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma
No standard of care for older patients with aggressive adult T-cell leukemia/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) every 2 weeks with mogamulizumab (Moga; Moga-CHOP-14) for older patients with untreated ATL. In this multicenter phase 2 trial, patients aged ≥66 years and those aged 56 to 65 years ineligible for transplantation received 6 cycles of Moga-CHOP-14, followed by 2 cycles of Moga monotherapy. The primary end point was 1-year progression-free survival (PFS). Secondary end points were the complete response (CR) rate, overall response rate (ORR), overall survival (OS), 1-year event-free survival (EFS), and safety. We also investigated the impact of CC chemokine receptor 4 (CCR4) mutation and Moga-associated cutaneous adverse events (cAEs) on PFS and OS. The study protocol was amended to allow the dosing interval to be extended to 21 days at the physician’s discretion. Among 48 evaluable patients, the 1-year PFS was 36.2% (90% confidence interval, 24.9-47.6), with a median follow-up of 1.6 years. The 1-year OS and EFS were 66.0% and 29.9%, respectively. CR and ORR were 64.6% and 91.7%. No unexpected toxicities were observed. Of 47 patients who received ≥2 cycles of CHOP, 20 (42.6%) received CHOP-14, among whom 12 (25.5%) completed 6 cycles. CCR4 mutation and Moga-associated cAEs were associated with better OS. This study showed that Moga-CHOP significantly improved PFS, although the optimal interval for CHOP remains undetermined. Moga-CHOP is now considered a preferable first-line treatment for this patient population. This trial was registered at https://jrct.mhlw.go.jp/en-top as #jRCTs041180130.
- Open Access
Hypomorphic Lig4 gene mutation in mice predisposes to Th1-skewing intestinal inflammation
Dysregulation of DNA double-strand break (DSB) repair leads to adaptive immunodeficiency, whereas the remaining lymphocytes are aberrantly activated and provoke inflammations. However, no model mice were available to consistently manifest inflammation under defective DSB repair. We generated mutant mice carrying a missense mutation p.W447C in the gene encoding DNA ligase IV (LIG4), critical for DSB repair. Lig4 W447C/W447C mice showed growth retardation and severe intestinal inflammations under adaptive immunodeficiency. The inflammations were featured by marked infiltration of T helper type 1 (Th1) cells and macrophages and was dependent on lymphocytes. When Ifng was deleted, Th2 and Th17 instead of Th1 cells drove the inflammations. Lig4 W447C/W447C mice showed expansion of oligoclonal T cells with T cell receptor α repertoire skewed towards more proximal 3’ V and 5’ J gene segments. Thus, our novel hypomorphic Lig4 mutant mice show that defective DSB repair leads to Th1-dependent intestinal inflammations under severe adaptive immunodeficiency.
Open AccessHypomorphic Lig4 gene mutation in mice predisposes to Th1-skewing intestinal inflammation
Dysregulation of DNA double-strand break (DSB) repair leads to adaptive immunodeficiency, whereas the remaining lymphocytes are aberrantly activated and provoke inflammations. However, no model mice were available to consistently manifest inflammation under defective DSB repair. We generated mutant mice carrying a missense mutation p.W447C in the gene encoding DNA ligase IV (LIG4), critical for DSB repair. Lig4 W447C/W447C mice showed growth retardation and severe intestinal inflammations under adaptive immunodeficiency. The inflammations were featured by marked infiltration of T helper type 1 (Th1) cells and macrophages and was dependent on lymphocytes. When Ifng was deleted, Th2 and Th17 instead of Th1 cells drove the inflammations. Lig4 W447C/W447C mice showed expansion of oligoclonal T cells with T cell receptor α repertoire skewed towards more proximal 3’ V and 5’ J gene segments. Thus, our novel hypomorphic Lig4 mutant mice show that defective DSB repair leads to Th1-dependent intestinal inflammations under severe adaptive immunodeficiency.
- Open Access
- 2 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Impact of epinephrine on neurological outcomes in out-of-hospital cardiac arrest after automated external defibrillator use in Japan
OHCA (out-of-hospital cardiac arrest) patients have improved neurological outcomes with public-access automated external defibrillator (PAD) use. However, the benefit of epinephrine administration after PAD use remains controversial. The purpose of the study was to investigate the impact of epinephrine administration on neurological outcomes in OHCA patients after PAD use. This study assessed 2,059,417 patients from the All-Japan Utstein Registry between 2005 and 2021. Patients were categorized into two groups: shockable and non-shockable rhythms on emergency medical service (EMS) arrival. Propensity score matching was used to adjust for various confounders and to analyze the impact of epinephrine administration on one-month favorable neurological outcomes. Criteria for bystander PAD was met by 11,629 (0.56%) of the enrolled patients. The mean age was 70 years with 71.9% male. Among them, 38.6% had shockable rhythms and 61.4% had non-shockable rhythms. After the matching, epinephrine administration negatively affected one-month favorable neurological outcome in patients with both shockable (14.7% vs. 41.1%, OR = 0.24, 95% CI = 0.19–0.31) and non-shockable rhythms (3.6% vs. 10.8%, OR = 0.31, 95% CI = 0.23–0.42). These findings suggest that epinephrine administration did not improve neurological outcomes in patients with OHCA after PAD use, providing insights to optimize EMS protocols for OHCA.
- 2 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessImpact of epinephrine on neurological outcomes in out-of-hospital cardiac arrest after automated external defibrillator use in Japan
OHCA (out-of-hospital cardiac arrest) patients have improved neurological outcomes with public-access automated external defibrillator (PAD) use. However, the benefit of epinephrine administration after PAD use remains controversial. The purpose of the study was to investigate the impact of epinephrine administration on neurological outcomes in OHCA patients after PAD use. This study assessed 2,059,417 patients from the All-Japan Utstein Registry between 2005 and 2021. Patients were categorized into two groups: shockable and non-shockable rhythms on emergency medical service (EMS) arrival. Propensity score matching was used to adjust for various confounders and to analyze the impact of epinephrine administration on one-month favorable neurological outcomes. Criteria for bystander PAD was met by 11,629 (0.56%) of the enrolled patients. The mean age was 70 years with 71.9% male. Among them, 38.6% had shockable rhythms and 61.4% had non-shockable rhythms. After the matching, epinephrine administration negatively affected one-month favorable neurological outcome in patients with both shockable (14.7% vs. 41.1%, OR = 0.24, 95% CI = 0.19–0.31) and non-shockable rhythms (3.6% vs. 10.8%, OR = 0.31, 95% CI = 0.23–0.42). These findings suggest that epinephrine administration did not improve neurological outcomes in patients with OHCA after PAD use, providing insights to optimize EMS protocols for OHCA.
- Open Access
- 14 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
C-Mannosyl tryptophan (CMW), a unique glycosylated amino acid, is considered to be produced by degradation of C-mannosylated proteins in living organism. Although protein C-mannosylation is involved in the folding and secretion of substrate proteins, the pathophysiological function in the hematological system is still unclear. This study aimed to assess CMW in the human hematological disorders. The serum CMW levels of 94 healthy Japanese workers were quantified using hydrophilic interaction liquid chromatography. Platelet count was positively correlated with serum CMW levels. The clinical significance of CMW in thrombocytosis of myeloproliferative neoplasms (T-MPN) including essential thrombocythemia (ET) were investigated. The serum CMW levels of the 34 patients with T-MPN who presented with thrombocytosis were significantly higher than those of the 52 patients with control who had other hematological disorders. In patients with T-MPN, serum CMW levels were inversely correlated with anemia, which was related to myelofibrosis (MF). Bone marrow biopsy samples were obtained from 18 patients with ET, and serum CMW levels were simultaneously measured. Twelve patients with bone marrow fibrosis had significantly higher CMW levels than 6 patients without bone marrow fibrosis. Collectively, these results suggested that CMW could be a novel biomarker to predict MF progression in T-MPN.
- 14 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessC-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
C-Mannosyl tryptophan (CMW), a unique glycosylated amino acid, is considered to be produced by degradation of C-mannosylated proteins in living organism. Although protein C-mannosylation is involved in the folding and secretion of substrate proteins, the pathophysiological function in the hematological system is still unclear. This study aimed to assess CMW in the human hematological disorders. The serum CMW levels of 94 healthy Japanese workers were quantified using hydrophilic interaction liquid chromatography. Platelet count was positively correlated with serum CMW levels. The clinical significance of CMW in thrombocytosis of myeloproliferative neoplasms (T-MPN) including essential thrombocythemia (ET) were investigated. The serum CMW levels of the 34 patients with T-MPN who presented with thrombocytosis were significantly higher than those of the 52 patients with control who had other hematological disorders. In patients with T-MPN, serum CMW levels were inversely correlated with anemia, which was related to myelofibrosis (MF). Bone marrow biopsy samples were obtained from 18 patients with ET, and serum CMW levels were simultaneously measured. Twelve patients with bone marrow fibrosis had significantly higher CMW levels than 6 patients without bone marrow fibrosis. Collectively, these results suggested that CMW could be a novel biomarker to predict MF progression in T-MPN.
- Open Access
- 18 June 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 40, 101107
Familial schwannomatosis carrying LZTR1 variant p.R340X with brain tumor: A case report
- 18 June 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 40, 101107
Open AccessFamilial schwannomatosis carrying LZTR1 variant p.R340X with brain tumor: A case report
- Open Access
- 7 February 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 76-88
Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for a positive hepatitis panel, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.
- 7 February 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 76-88
Open AccessPredictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for a positive hepatitis panel, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.
- Open Access
- 11 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52127
Post-infarction Left Ventricular Free Wall Rupture Diagnosed by Contrast-Enhanced Computed Tomography: A Case Report
A 70-year-old Japanese woman with hypertension, dyslipidemia, and diabetes mellitus complained of abdominal discomfort and vomiting and was brought to our emergency department by ambulance two days later with impaired consciousness. Her vital signs suggested shock with a heart rate of 120 bpm. Electrocardiogram and initial transthoracic echocardiography suggested an inferior wall ST-elevation myocardial infarction, but the altered consciousness was inconsistent. Contrast-enhanced computed tomography was urgently performed to further clarify the cause. It revealed pericardial effusion and apparent extravasation from the left ventricular wall, confirming the early definitive diagnosis of left ventricular free wall rupture. The patient underwent successful emergent surgical repair without sequelae. Differential diagnosis of left ventricular free wall rupture is important in patients with ST-elevation myocardial infarction and impaired consciousness. Contrast-enhanced computed tomography allows early diagnosis and treatment of this life-threatening complication.
- 11 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52127
Open AccessPost-infarction Left Ventricular Free Wall Rupture Diagnosed by Contrast-Enhanced Computed Tomography: A Case Report
A 70-year-old Japanese woman with hypertension, dyslipidemia, and diabetes mellitus complained of abdominal discomfort and vomiting and was brought to our emergency department by ambulance two days later with impaired consciousness. Her vital signs suggested shock with a heart rate of 120 bpm. Electrocardiogram and initial transthoracic echocardiography suggested an inferior wall ST-elevation myocardial infarction, but the altered consciousness was inconsistent. Contrast-enhanced computed tomography was urgently performed to further clarify the cause. It revealed pericardial effusion and apparent extravasation from the left ventricular wall, confirming the early definitive diagnosis of left ventricular free wall rupture. The patient underwent successful emergent surgical repair without sequelae. Differential diagnosis of left ventricular free wall rupture is important in patients with ST-elevation myocardial infarction and impaired consciousness. Contrast-enhanced computed tomography allows early diagnosis and treatment of this life-threatening complication.